Method for preparing colon cancer chemotherapy medicament

Abstract

The invention provides a method for preparing colon cancer chemotherapy medicament, which comprises the following steps: weighting the raw material of plasma in the blood bank, centrifuging the plasma, adjusting the density of the plasma, and extracting low-density lipoprotein from the plasma; purifying the low-density lipoprotein to obtain the carrier of the target medicament; compounding the low-density lipoprotein with the target aclacinomycin medicament for treating colon cancer; and injecting the compound of the low-density lipoprotein and the target aclacinomycin medicament into the body of the patient whose blood type is the same as the raw material of plasma to treat the colon cancer. The clinical practice shows that the injection of the compound of the low-density lipoprotein and the target aclacinomycin medicament has the satisfactory effect for treating the colon cancer clinically and can not cause obvious toxic and side reaction of chemotherapy. Used for treating the colon cancer of 185 patients, the injection of the compound of the low-density lipoprotein and the target aclacinomycin medicament achieves the effective rate of 100 percent and the survival rate of more than 96 percent in three years, thereby having high popularization and application values.

Description

technical field [0001] The invention relates to a preparation method of a cancer chemotherapy preparation, in particular to a preparation method of a colon cancer chemotherapy drug. Background technique [0002] With the aggravation of environmental pollution and changes in diet structure, the incidence and mortality of colon cancer are increasing year by year, seriously endangering the health of the people. In the treatment plan of colon cancer, chemotherapy is still the main means in its comprehensive treatment measures. At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage and toxic...

AI Technical Summary

Problems solved by technology

At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage and toxicity to normal cells, the medical community has tried many times to use antibodies, liposomes, hormones and other macromolecules as tumor chemotherapy drugs. Carriers, in order to increase the targeting of drugs, that is, "targeted therapy"

However, a major problem in the actual clinical application process is that the reticuloendothelial system of the liver and spleen removes these complexes in the blood as foreign harmful substances and quickly removes them from the blood stream, thereby reducing the impact of the drug-macromolecule complex on the bloodstream. The time of action of tumor cells affects the therapeutic effect of drugs